52 results about "Abnormal glucose tolerance" patented technology

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP alpha, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of / or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

The invention discloses a golden camellia leaf extract and application thereof. The extract comes from plant leaves of golden camellia, and the iconic component tea polyphenol of the extract accounts for 3.5-20 mass percent. The preparation method comprises the following steps: adding water into the plant leaves of golden camellia, extracting, filtering, adding water into the filter residue for extracting for 1-5 times, filtering, merging the obtained filtrate, and drying under reduced pressure, thereby obtaining a product, wherein the step of adding water into the plant leaves and the filter residue for extracting comprises the following sub-steps: adding water in an amount of 5-30 times that of the weight of the material, heating, closing the fire after the solution is boiling, performing hot dipping for 10-180 minutes, heating and closing the fire after the solution is boiling, and performing hot dipping for 1-180 minutes. The extract mainly refers to a polyphenol extract of golden camellia leaves, and the preparation method is simple and feasible and is suitable for industrial production; and moreover, the polyphenol extract of golden camellia leaves is obvious in effect of reducing blood sugar, can be used for preparing medicines, foods and health products for reducing blood sugar or preparing medicines for treating related diseases caused by abnormal glucose tolerance, insulin resistance, metabolic syndrome and primary hyperglycemia and is wide in application range.

The invention provides an application of alpha-mangostin for prevention and treatment of diabetes mellitus. Alpha-mangostin can be used for decreasing blood glucose of diabetics, increasing glucose tolerance and improving symptoms of polydipsia, polyuria, polyphagia, emaciation and thirsty of the diabetics, can also be used for lowering high-fat-diet-induced obesity mouse total cholesterol content, has a cholesterol lowering effect, is capable of improving abnormality of the high-fat-diet-induced mouse glucose tolerance, and has functions of preventing and delaying obese patients from getting diabetes mellitus.

An agent for improving abnormal glucose tolerance or a preventive and / or a remedy for diseases caused by abnormal glucose tolerance containing a chymase inhibitor as the active ingredient. Examples of the diseases caused by abnormal glucose tolerance include diabetes and / or complications of diabetes. Examples of the complications of diabetes include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinemia, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, vasculitis, brain infarction, hypertension, renal insufficiency, neuropathy, nephritis, renal aneurysm, renal infarction, obesity and so on.

The present invention provides a composition for improving glucose tolerance to patients having diabetic hyperglycemia and people having pre-diabetes, i.e., abnormal glucose tolerance. The composition helps control the blood glucose level, prevents diabetic complications, and can be administered over a long term due to its high safety. The composition containing a coenzyme Q, in particular, a reduced coenzyme Q10, as the main component improves the impaired glucose tolerance of diabetes patients, satisfactorily controls the blood glucose level, and decreases the blood glycosylated hemoglobin level.

The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and / or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.

The invention relates to blood sugar reducing healthy tea and a preparation method thereof. The blood sugar reducing healthy tea is prepared by the following steps: using guayaba leaves, cassia bark, momordica grosvenori and jasmine tea as raw materials; cleaning and removing impurities and rotten bad raw materials, drying at 50-85 DEG C and crushing, sieving by a vibration sieve; taking 20-60mu of raw materials, mixing according to the proportion, sterilizing and packaging. The invention has the advantages of special formulation, accurate treatment effect, convenient use, low cost and safety without toxic and side effects, has the functions of clearing heat and enriching the saliva, tonifying spleen and resolving dampness, and reducing blood sugar and lipid, and is suitable to patients with abnormal glucose tolerance and mild diabetes mellitus. Tests show that the invention has the functions of reducing blood sugar, lightening insulin resistance, increasing the sensitivity of insulin, protecting the function of Beta cells, and lowering serum total cholesterin and serum triglyceride without toxic and side effects.

Disclosed are methods for improving insulin sensitivity and / or glucose metabolism in individuals with abnormal glucose tolerance. Such methods may be used in treating conditions associated with abnormal glucose tolerance and metabolism in mammals, including insulin resistance, insulin resistant metabolic syndrome, impaired glucose tolerance, impaired fasting glucose, hypertension, hypercholestemia and diabetes, particularly Type 2 diabetes.

The invention which relates to a crude tea composition for controlling abnormal glucose tolerance belongs to the technical field of food compositions with both functions of drugs and foods. The crude tea composition is prepared from the following raw materials, by weight, 6-10 parts of Dafo Longjing tea, 2-10 parts of loquat leaf, 2-10 parts of mulberry leaf, 2-10 parts of lotus leaf, and 2-10 parts of honeysuckle flower. The crude tea composition for controlling the abnormal glucose tolerance, which has a reasonable ratio and has the efficacies of heat clearing and blood cooling, stomach harmonization and phlegm and moisture reduction, thirst quenching, glucose and lipid lowering and the like is suitable for patients with abnormal glucose tolerances, and is especially suitable for obese people. The cure rate of the abnormal glucose tolerance treated by the crude tea composition of the invention can achieve more than 90%; and compared with costs of present drugs, the cost of the crudetea composition of the invention is reduced by more than 10%.

Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the Lactobacillus sp. and Lactococcus sp. and / or cultures thereof, while also providing a beverage, food or feed containing said visceral fat reducing agent.

The invention relates to a method for constructing a type II diabetes model by combining high-fat feeding with streptozotocin induction. According to the method, the high-fat and high-sugar diet is given by simulating the morbidity process of human type II diabetes, so that wide insulin resistance of mice is caused, but the blood sugar is not obviously increased. STZ is a powerful alkylating agentand can cause DNA alkylation, the DNA chain is broken, so that glycosylation of poly adenosinediphosphate ribose is activated, NO is released, the content of nicotinamide adenine in cells is rapidlyreduced, pancreatic beta cells are damaged or necrotic, insulin secretion is reduced, at the moment, most mice have abnormal glucose tolerance, and animal hyperglycemia is induced. The method has themain beneficial effects that the diabetes model of the female ICR mouse is successfully established through the research, and the pathological structure and biochemical detection change trend of the mouse are basically consistent with those of type II diabetes of human beings.

The invention discloses application of Quanmasu in preparation of drugs for treatment of diabetes. The Quanmasu is prepared by uniform mixing of an industrial hemp fructus cannabis extract and 99.7-0.3 parts by weight of industrial hemp Huomasu. Experiments prove that the Quanmasu can significantly reduce the blood glucose value of animals with diabetes, improve abnormal glucose tolerance, improve abnormal lipid metabolism, also has an inhibitory effect on blood glucose rise in normal animals after oral taking of glucose, and has no obvious influence on the blood glucose of normal animals. Drug therapy clinical observation is carried out on 100 cases of patients with type II diabetes and finds that a Quanmasu active component has a blood glucose lowering effect and the total effective rate reaches 95%. Quanmasu has medication safety and has definite blood glucose lowering efficacy.

The invention discloses application of triacetyl-3-hydroxyphenyl adenosine, as shown in Formula (I), in preparing medicines for preventing, relieving or treating insulin resistance and related diseases, wherein the insulin resistance related diseases include type II diabetes, abnormal glucose tolerance, hyperinsulinemia, impaired glucose tolerance, hypertension, coronary disease, obesity and non-alcoholic fatty liver disease. Specifically, the triacetyl-3-hydroxyphenyl adenosine disclosed by the invention can improve the insulin sensitivity of peripheral tissues and the glucose tolerance of a body and the triacetyl-3-hydroxyphenyl adenosine can reduce insulin content, so that insulin resistance is improved (as shown in the Description).

The invention discloses a traditional Chinese medicine composition capable of tonifying spleen, and application of the traditional Chinese medicine composition. The formula of the traditional Chinesemedicine composition consists of the following ingredients: 15-25 parts of radix puerariae lobatae, 12-18 parts of radix salviae miltiorrhizae, 25-35 parts of atractylodis macrocephalae rhizome, 25-35parts of radix pseudostellariae and 8-12 parts of phellodendri chinensis cortex. From a formula capable of treating diabetes mellitus through a treatise on spleen and stomach, the traditional Chinesemedicine composition has the efficacy of tonifying spleen, dredging collaterals, clearing heat and invigorating the circulation of blood, and is used for treating thirsty, tuberculosis, lumps in theabdomen and the like caused by spleen deficiency, hotness, suffocating and venation stasis, wherein symptoms include polydipsia due to thirst, diuresis, bitter taste, body fatness, chest stuffiness, vomiting, nausea, fatigue, weakness, loose stool, limb paralysis and the like. The traditional Chinese medicine composition has an obvious curative effect on people with the above syndromes, includingfamily history of diabetes, diabetes high risk groups, prediabetes, early diabetes, abnormal glucose tolerance, obesity, hyperlipemia, hyperuricemia, metabolic syndromes and the like.

The invention provides a new alpha-glucosidase inhibitor which comes from cinnamomum cassia which is a traditional Chinese medicine, namely cinnamic aldehyde, and an application of the cinnamic aldehyde in preparing medicament for preventing and curing diabetes, abnormal glucose tolerance and adiposis and the like, or health products.

The invention discloses a 2-pyrrolidine substitution-hydrocinnamoyl pyrrolidine derivant which is the compound in formula 1 or an acceptable salt thereof in pharmacy, wherein, R1 or R2 is respectively hydrogen, cyano-group, acidic group, ester group, acyl group, amide group or substitution amide group independently; the hexagram symbol stands for a chiral centre. The invention further discloses a method for preparing the compound and the application thereof for preparing or preventing noninsulin-dependent diabetes mellitus, adiposis, arthritis or other glucose tolerance abnormality diseases.

The invention relates to application of a clam meat oligosaccharide in preparation of drugs or health foods for decreasing blood sugar and preventing and treating diabetes and a preparation method of the clam meat oligosaccharide. The optimized molecular weight range of the clam meat oligosaccharide is a 500-2000 clam meat oligosaccharide compound, and the total content is higher than 50 percent. Experimental results show that the clam meat oligosaccharide can significantly inhibit the blood sugar level and improve the glucose tolerance of model mice with alloxan-induced diabetes; the clam meat oligosaccharide has a significant effect of decreasing the blood sugar for mice with II type diabetes induced by high fat diet and STZ and the main expressions are as follows: the abnormal glucose tolerance of the mice with the II type diabetes is improved, the rise of plasma HbA1c is inhibited, the contents of hepatic glycogen and muscle glycogen are significantly increased, the utilization of hepatic glycogen is enhanced, the generation of glycogen is inhibited, the glucagon secretion is inhibited, the reserve of glycogen is enhanced, and the heteroplasia of sugar is reduced. Acute toxicity tests and researches show that the clam meat oligosaccharide has no toxic or side effects and is high in safety.

The invention discloses a Japanese galangal flower extract for improving sugar tolerance and a usage of the Japanese galangal flower extract. The extract is extracted from the raw material Japanese galangal flower, wherein the Japanese galangal flower is flower of Alpinia japonica Miq of the Alpinia genus of the ginger family. The Japanese galangal flower extract is capable of obviously improving sugar tolerance and decreasing fasting or postprandial blood glucose levels of the patients, so that the Japanese galangal flower extract plays a significant regulatory role in the blood glucose level of the patient with abnormal glucose tolerance, hyperglycemia or diabetes; thus, the Japanese galangal flower extract can be developed into drugs, health foods or functional foods for the patients with abnormal glucose tolerances. The Japanese galangal flower extract has relatively wide applicable crowd.

The invention discloses a flavane compound shown in a formula I, a preparation method thereof and an application of medicine and health product for treating and / or preventing obesity and diabetes and abnormal glucose tolerance. The flavane compound is obtained from a flavane polymer (taking ECG as a polymerization unit) in rhodiola crenulata and the flavane polymer (taking EGCG as the polymerization unit) in rhodiola kirilowii through derivatization of a thiolysis reagent connected to different functional groups. The pharmacological result displays the flavane compound has good pharmacological effect on the hypoglycemic aspect.

The invention provides polypeptide tea for blood glucose reduction and a manufacturing method of the polypeptide tea. The tea comprises a bitter gourd extract, a rhizoma polygonati odorati extract, and a radix puerariae extract, and is abundant in effective components including vitamins, trace elements, amino acids, tea polysaccharide, rhizoma polygonati odorati polysaccharide, steroidal glycoside, daidzein, daidzin, puerarin, and puerarin-7-xyloside, and has the efficacy of clearing heat and engendering fluid, reducing blood glucose and wiping off grease, and resolving stasis and free the collateral vessels. The tea is suitable for patients who has abnormal glucose tolerance and suffers from slight diabetes, and has the efficacy of reducing fasting blood glucose. The polypeptide tea for blood glucose reduction has properties as medicines and takes like tea, and the formula of the tea is based on the traditional Chinese medicine curative theory of yin-yang balance and healthy qi reinforcement.

The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.

The invention relates to a health-care tea for regulating blood sugar level and a preparation method thereof. The health-care tea is prepared by taking balsam pear, notoginseng, cinnamon and fructus momordicae as raw materials, selecting, removing impurities and deteriorated raw materials, drying at 50 to 85 DEG C, grinding, screening with a vibrating screen, taking the raw materials with the diameter of 20 to 60 meshes, mixing the raw materials in a proper proportion, sterilizing and packaging. The health-care tea has the advantages of unique preparation, exact curative effect, convenient use, economy, safety, effects of removing heat and dampness, activating blood and dissolving stasis, and regulating blood sugar level and blood fat level, no toxic or side effect, and suitability for patients suffering from abnormal glucose tolerance and mild diabetes. Experimental research shows, that the health-care tea has the functions of reducing blood sugar, relieving insulin resistance, increasing insulin sensitivity, protecting beta cell, and reducing serum total cholesterol and serum triglyceride without toxic or side effect.

The invention relates to a benzoxazole derivative. The benzoxazole derivative is (5-methylbenzoxazole-2-phenyl)-3'-methoxybenzamide, can be applied to silent information regulator agonist SIRT1 and preparation of medicaments for reducing, improving, preventing and treating II-type diabetes mellitus or hyperglycemia, abnormal glucose tolerance, dyslipidemia and complications caused by those diseases due to the II-type diabetes mellitus. In-vitro saccharomycete experiments prove that the SIRT1 agonist, such as benzoxazole derivative (5-methylbenzoxazole-2-phenyl)-3'-methoxybenzamide can be used for promoting the growing activity of saccharomycetes, reinforcing metabolic growth, improving the activity of SOD (superoxide dismutase), Cu-Zn SOD and CAT (chloramphenicol acetyl transferase) in the body of drosophila melanogaster, reducing the content of MDA (methylene dioxyamphetamine), and increasing the expression quantity of anti-oxidation gene CAT mRNA (messenger ribonucleic acid).

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided:

The invention belongs to oral traditional Chinese medicine granules, and particularly relates to concentrated sugar-free granules used for pharyngitis treatment and a preparation method thereof, aiming at treating symptoms caused by pharyngeal local inflammation and sputum stimulation, such as sore throat, foreign body sensation, dry cough and ungratifying coughing of phlegm. The concentrated sugar-free granules are particularly suitable for diabetes patients and patients with abnormal glucose tolerance. Main medicines of the concentrated sugar-free granules comprise following materials by weight: 1.5 parts of radix scrophulariae, 1.5 parts of radix ophiopogonis, 1.5 parts of balloonflower root, 2.5 parts of asiatic moonseed, 2.5 parts of wild chrysanthemum flower, 1 part of dried orange peel, 1.5 parts of radix clematidis and 1 part of liquorice. The concentrated sugar-free granules have functions of clearing away heat, nourishing yin, relieving sore-throat and eliminating swell and are suitable for treatment of acute and chronic pharyngitis of various kinds. The application population is broadened.

This invention relates to methods for predicting likelihood of a subject having abnormal glucose tolerance based on analyzing a combination of three or more biomarkers relating to specific physiological processes. This invention also relates to methods of accessing insulin sensitivity in a subject based on analyzing a combination of three or more biomarkers relating to specific physiological processes. The method has a clinical utility in correct and quick assessment of a subject's glucose tolerance and risk of developing diabetes or cardio-diabetic conditions and comorbidities.

The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and / or renal disease associated anemia, including therapeutic compositions, methods and devices.

The invention discloses a combined medicine containing microorganisms and a hypoglycemic and lipid-lowering medicine, and relates to the technical field of strain separation and application. The combined medicine containing the microorganisms and the blood glucose and lipid lowering medicine can be applied to treatment or prevention of liver function impairment, liver function impairment related diseases, diabetes mellitus, obesity and obesity related diseases. The inventor verifies that the combined medicine containing the microorganisms and the hypoglycemic and lipid-lowering medicine has the technical effect of synergistic interaction, the combined medicine has the treatment effect better than that of the single application of the microorganisms or the single application of the hypoglycemic and lipid-lowering medicine, and the microorganisms can enhance the weight losing effect of the hypoglycemic and lipid-lowering medicine, improve abnormal glucose tolerance and reduce fasting blood glucose. In addition, the combined medicine has no toxic or side effect on the kidney and can reduce the weight of the liver.

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided: